Human Genome Sciences Reports Positive Interim Results Of Phase 2 Trials Of Albuferon(TM) With Ribavirin In Patients With Chronic Hepatitis C

Wed, 01 Nov 2006 02:00 PM EST

... Human Genome Sciences, Inc. (Nasdaq: HGSI) today reported the interim results of two Phase 2 clinical trials to evaluate the efficacy and safety of Albuferon(TM) (albumin- interferon alpha 2b) in combination with ribavirin in patients with chronic hepatitis C. [click link for full article] ...